Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Current Liabilities: 2016-2024

Historic Total Current Liabilities for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $80.9 million.

  • Akebia Therapeutics' Total Current Liabilities rose 102.98% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year increase of 102.98%. This contributed to the annual value of $80.9 million for FY2024, which is 18.98% down from last year.
  • Per Akebia Therapeutics' latest filing, its Total Current Liabilities stood at $80.9 million for FY2024, which was down 18.98% from $99.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Total Current Liabilities ranged from a high of $261.1 million in FY2021 and a low of $80.9 million during FY2024.
  • Its 3-year average for Total Current Liabilities is $103.4 million, with a median of $99.9 million in 2023.
  • As far as peak fluctuations go, Akebia Therapeutics' Total Current Liabilities surged by 39.49% in 2021, and later plummeted by 50.38% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Total Current Liabilities (MRY) stood at $187.1 million in 2020, then surged by 39.49% to $261.1 million in 2021, then crashed by 50.38% to $129.5 million in 2022, then fell by 22.90% to $99.9 million in 2023, then decreased by 18.98% to $80.9 million in 2024.
  • Its Total Current Liabilities stands at $80.9 million for FY2024, versus $99.9 million for FY2023 and $129.5 million for FY2022.